PPARα as a therapeutic target in inflammation-associated diseases

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 11, 2012, Pages 1113-1125

  Gervois, Philippe ^a   Mansouri, Roxane M ^a  

^a UNIV LILLE   (France)

Author keywords

C EBP; IL 1; IL 6; Inflammation; NF B; PPAR ; STAT3

Indexed keywords

ALEGLITAZAR; ANTIINFLAMMATORY AGENT; GFT 505; GLUCOCORTICOID; INDEGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; UNCLASSIFIED DRUG;

CELL TYPE; DRUG TARGETING; ENTERITIS; HEART VENTRICLE HYPERTROPHY; HEPATITIS; HUMAN; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN STRUCTURE; RESPIRATORY TRACT INFLAMMATION; REVIEW; VASCULITIS;

ANIMALS; HUMANS; INFLAMMATION; LIGANDS; PPAR ALPHA; PROTEIN CONFORMATION;

EID: 84867519027     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.715633     Document Type: Review

References (93)

1. Tsai M-J, O'Malley B. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86
2. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: The second decade. Cell 1995;83:835-9
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999;20:649-88
4. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor- alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998;139:2748-54
5. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50
6. Harmon GS, Lam MT, Glass CK. PPARs and lipid ligands in inflammation and metabolism. Chem Rev 2011;111:6321-40
7. Choi JM, Bothwell AL. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 2012;33:217-22
8. Cunard R, DiCampli D, Archer DC, et al. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 2002;169:6806-12
9. Gervois P, Chopin-Delannoy S, Fadel A, et al. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol endocrinol 1999;13:400-9
10. Marx N, Duez H, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors and atherogenesis : Regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78
11. Gervois P, Fruchart JC, Staels B. Drug insight: Mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007;3:145-56
12. Rotman N, Wahli W. Fatty acid synthesis and PPARalpha hand in hand. Chem Biol 2009;16:801-2
13. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-3
14. Guzman M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 2004;279:27849-54
15. Chakravarthy MV, Lodhi IJ, Yin L, et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 2009;138:476-88
16. Gillies PJ, Bhatia SK, Belcher LA, et al. Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil. J Lipid Res 2012;53(8):1679-89
17. Wu D. Modulation of immune and inflammatory responses by dietary lipids. Curr Opin Lipidol 2004;15:43-7
18. Devchand PR, Keller H, Peters JM, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996;384:39-43
19. Cowart LA, Wei S, Hsu MH, et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator- activated receptor ligands. J Biol Chem 2002;277:35105-12
20. Forman BM, Chen J, Evans R. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997;94:4312-17
21. D'Agostino G, LaRana G, Russo R, et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan- induced paw edema in mice. J Pharmacol Exp Ther 2007;322:1137-43
22. D'Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009;613:54-9
23. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-54
24. Marx N, Sukhova G, Collins T, et al. PPARalpha. activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31
25. Xu X, Otsuki M, Saito H, et al. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology 2001;142:3332-9
26. Crisafulli C, Cuzzocrea s. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages. Shock 2009;32:62-73
27. Gervois P, Kleemann R, Pilon A, et al. Global suppression of IL-6-induced acute phase response gene expression after in vivo chronic treatment with the peroxisome proliferator-activated receptor alpha activator fenofibrate. J Biol Chem 2004;279:16154-60
28. Kleemann R, Gervois P, Verschuren L, et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing p50-NF-kappaB-C/EBP-beta complex formation. Blood 2003;101:545-51
29. Baumann H, Morella KK, Campos SP, et al. Role of CAAT-enhancer binding protein isoforms in the cytokine regulation of acute-phase plasma protein genes. J Biol Chem 1992;267:19744-51
30. Kordula T, Travis J. The role of Stat and C/EBP transcription factors in the synergistic activation of rat serine protease inhibitor-3 gene by interleukin-6 and dexamethasone. Biochem J 1996;313:1019-27
31. Zauberman A, Lapter S, Zipori D. Smad proteins suppress CCAAT/enhancerbinding protein (C/EBP) beta- and STAT3-mediated transcriptional activation of the haptoglobin promoter. J Biol Chem 2001;276:24719-25
32. Yoo JY, Wang W, Desiderio S, Nathans D. Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha 2-macroglobulin promoter. J Biol Chem 2001;276:26421-9
33. Schuringa JJ, Timmer H, Luttickhuizen D, et al. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 response element (IRE). Cytokine 2001;14:78-87
34. Paumelle R, Blanquart C, Briand O, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 2006;98:361-9
35. Bougarne N, Paumelle R, Caron S, et al. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB. Proc Natl Acad Sci USA 2009;106:7397-402
36. Genovese T, Esposito E, Mazzon E, et al. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol Res 2009;59:338-50
37. Riccardi L, Mazzon E, Bruscoli S, et al. Peroxisome proliferator- activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. Shock 2009;31:308-16
38. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000;275:36703-7
39. Gocke AR, Hussain RZ, Yang Y, et al. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol 2009;182:4479-87
40. Francois M, Richette P, Tsagris L, et al. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 2006;54:1233-45
41. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-26
42. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790-3
43. Delerive P, Martin-Nizard F, Chinetti G, et al. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway. Circ Res 1999;85:394-402
44. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:658-63
45. Gizard F, Amant C, Barbier O, et al. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16. J Clin Invest 2005;115:3228-38
46. Shu H, Wong B, Zhou G, et al. Activation or PPARalpha of gamma reduces secretion of matrix metalloproteinase 9 but not interleukin-8 from human monocytic THP-1 cells. Biochem Biophys Res Com 2000;267:345-9
47. Marx N, Mackman N, Schonbeck U, et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001;103:213-19
48. Neve BP, Corseaux D, Chinetti G, et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001;103:207-12
49. Hourton D, Delerive P, Stankova J, et al. Oxidized low-density lipoprotein and peroxisome proliferator-activated receptor alpha down-regulate plateletactivating factor receptor expression in human macrophages. Biochem J 2001;354:225-32
50. Duez H, Chao YS, Hernandez M, et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptoralpha. agonist fenofibrate in mice. J Biol Chem 2002;277:48051-7
51. Hennuyer N, Tailleux A, Torpier G, et al. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1897-902
52. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004;114:1538-40
53. Tordjman K, Bernal-Mizrachi C, Zemany L, et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 2001;107:1025-34
54. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progress of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53
55. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43
56. DAIS. DAIS: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10
57. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
58. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
59. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-8
60. ACCORD SG. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
61. Lorenzo O, Picatoste B, Ares-Carrasco S, et al. Potential role of nuclear factor-kappaB in diabetic cardiomyopathy. Mediators inflamm 2011;2011:ID 652097
62. Gaspar-Pereira S, Fullard N, Townsend PA, et al. The NF-kB subunit c-Rel stimulates cardiac hypertrophy and fibrosis. Am J Pathol 2012;180:929-39
63. Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NF-kB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 2012;110:1077-86
64. Smeets PJ, Teunissen BE, Planavila A, et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem 2008;283:29109-18
65. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 2011;90:276-84
66. Irukayama-Tomobe Y, Miyauchi T, Sakai S, et al. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2- terminal kinase pathway. Circulation 2004;109:904-10
67. Karbowska J, Kochan Z, Smolenski RT. Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart. Cell Mol Biol Lett 2003;8:49-53
68. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-47
69. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity 2003;19:641-4
70. Xu J, Chavis JA, racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006;176:95-105
71. Xu J, Storer PD, Chavis JA, et al. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 2005;81:403-11
72. Xu J, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: Relevance to multiple sclerosis. J Neurochem 2007;103:1801-10
73. Wang G, Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor alpha activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res 2011;70:230-7
74. Dasgupta S, Roy A, Jana M, et al. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol 2007;72:934-46
75. D'Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009;613:54-9
76. Gray E, Ginty M, Kemp K, et al. Peroxisome proliferator-activated receptor-a agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. Eur J Neurosci 2011;33:1421-32
77. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation. Pulm Pharmacol Ther 2008;21:324-30
78. Delayre-Orthez C, Becker J, Guenon I, et al. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 2005;6:91
79. Delayre-Orthez C, Becker J, Auwerx J, et al. Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate. Eur J Pharmacol 2008;581:177-84
80. Azuma YT, Nishiyama K, Matsuo Y, et al. PPARalpha contributes to colonic protection in mice with DSS-induced colitis. Int Immunol Pharmacol 2010;10:1261-7
81. Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 2007;133:108-23
82. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006;55:1341-9
83. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14
84. Hoffmeister A, Rothenbacher D, Bazner U, et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001;87:262-6
85. Dhainaut JF, Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001;29:S42-S7
86. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44
87. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5
88. Zambon A, Gervois P, Pauletto P, et al. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: Clinical and experimental evidence. Arterioscler Thromb Vasc Biol 2006;26:977-86
89. Gervois P, Vu-Dac N, Kleemann R, et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 2001;276:33471-7
90. Mansouri RM, Bauge E, Staels B, Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology 2008;149:3215-23
91. Videla LA. Liver NF-kappaB and AP-1 activation and PPARalpha expression are negatively correlated in obese patients: pro-inflammatory implications. Clin Nutr 2010;29:687-8
92. Pettinelli P, Del Pozo T, Araya J, et al. Enhancement in liver SREBP-1c/PPARalpha ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. BBA 2009;1792:1080-6
93. Moustafa T, Fickert P, Magnes C, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012;142:140-51